Am J Perinatol 2020; 37(11): 1110-1114
DOI: 10.1055/s-0040-1714060
Original Article

Universal SARS-Cov-2 Screening in Women Admitted for Delivery in a Large Managed Care Organization

Michael J. Fassett
1   Department of Maternal-Fetal Medicine, Kaiser Permanente West Los Angeles Medical Center, Los Angeles, California
,
Lawrence D. Lurvey
2   Southern California Permanente Medical Group, Pasadena, California
,
Lyn Yasumura
3   Department of Obstetrics and Gynecology, Kaiser Permanente Baldwin Park Medical Center, Baldwin Park, California
,
Marielle Nguyen
4   Department of Neonatal Medicine, Kaiser Permanente Anaheim Medical Center, Anaheim, California
,
Joseph J. Colli
5   Department of Neonatal Medicine, Kaiser Permanente South Bay Medical Center, Los Angeles, California
,
Marianna Volodarskiy
6   Kaiser Foundation Hospitals, Pasadena, California
,
Jonathan C. Gullett
7   Southern California Permanente Medical Group Regional Reference Laboratories, North Hollywood, California
,
David Braun
8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
,
Alex Fong
9   Department of Maternal-Fetal Medicine, Kaiser Permanente Irvine Medical Center, Irvine, California
,
Neha Trivedi
10   Department of Maternal-Fetal Medicine, Kaiser Permanente San Diego Medical Center, San Diego, California
,
Katia Bruxvoort
8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
,
Vicki Chiu
8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
,
Darios Getahun
8   Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California
11   Department of Health Systems Science at the Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California
› Author Affiliations
Funding This study was supported by Kaiser Permanente Direct Community Benefit Funds.

Abstract

Objective The coronavirus disease 2019 (COVID-19) pandemic has created a need for data regarding the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnant women. After implementing universal screening for COVID-19 in women admitted for delivery, we sought to describe the characteristics of COVID-19 in this large cohort of women.

Study Design An observational study of women admitted to labor and delivery units in Kaiser Permanente Southern California (KPSC) hospitals between April 6 and May 11, 2020 who were universally offered testing for SARS-CoV-2 infection (n = 3,963). Hospital inpatient and outpatient physician encounter, and laboratory records were used to ascertain universal testing levels, test results, and medical and obstetrical histories. The prevalence of SARS-CoV-2 infection was estimated from the number of women who tested positive during labor per 100 women delivered.

Results Of women delivered during the study period, 3,923 (99.0%) underwent SARS-CoV-2 testing. A total of 17 (0.43%; 95% confidence interval: 0.23–0.63%) women tested positive, and none of them were symptomatic on admission. There was no difference in terms of characteristics between SARS-CoV-2 positive and negative tested women. One woman developed a headache attributed to COVID-19 3 days postpartum. No neonates had a positive test at 24 hours of life.

Conclusion The findings suggest that in pregnant women admitted for delivery between April 6 and May 11, 2020 in this large integrated health care system in Southern California, prevalence of SARS-CoV-2 test positive was very low and all patients were asymptomatic on admission.

Key Points

  • The prevalence of SARS-CoV-2 infection in a large diverse cohort of term pregnant women was 0.43%.

  • 99% of women accepted SARS-CoV-2 screening on admission to labor and delivery.

  • All women with positive test results were asymptomatic at the time of testing.



Publication History

Received: 28 May 2020

Accepted: 11 June 2020

Article published online:
03 July 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.